Can we count your visit with Google Analytics? No ads, no profiles. Details
HALO
NASDAQHealth Care · Biotechnology
Each weekday: the watchlist of pullbacks inside uptrends, every new ticker teardown, and the bubble shifts that move names like this one. Free. Education, not advice.
Free when you join: the $HOOD Teardown Dossier (Robinhood Markets), the full desk file we sell in the shop. One per new reader.
No spam. One email per day max, unsubscribe in one click. Pro ($49/mo) includes every dossier and report in the shop.
Structural: ENHANZE is the de facto standard for SC-converting blockbuster biologics - 13+ partnered programs, royalty stack compounds as each partner launches new SC formulations and gets uptake. Royalty model = ~85% gross margins, minimal R&D burden vs. owning a pipeline.
Mid-2027 cliff: Darzalex SC composition-of-matter IP expires, which threatens the largest royalty stream ($JNJ Darzalex Faspro ~50% of royalty revenue).
(1) Royalty mix shifts as $ARGX Vyvgart Hytrulo, $BMY Opdivo SC, $ROG Ocrevus SC, $JNJ Rybrevant SC ramp - reduces Darzalex concentration. (2) ENHANZE platform IP extends beyond 2030 on newer co-formulations (different patent families than Darzalex 2027 cliff).
(3) Buybacks aggressive - board has repeatedly authorized large repurchase programs, float shrinking. (4) Pharma pipeline of IV-to-SC conversions still has multi-year runway (oncology, immunology, rare disease). (5) Auto-injector business (Antares) adds proprietary product revenue, less royalty-cliff-sensitive.
(1) Darzalex 2027 IP cliff is the dominant overhang - biosimilar SC versions could compress the largest royalty line. (2) Partner concentration: $JNJ + $BMY + $ROG = bulk of revenue, partner business decisions (pricing, switching IV-only) flow straight through.
(3) Alternative SC delivery tech (Merck's MK-1084 platform, $ALT competing hyaluronidase variants) could erode pricing power on new deals. (4) Litigation/patent challenges from biosimilar makers ongoing. (5) Royalty model means no upside from operational leverage - top-line is capped by partner sell-through.
It reads our $HALO data (thesis, key levels, peers, a year of prices) and any chart screenshot you paste, then explains the setup in plain English. Free with an email login, 5 questions a day. Education only: it never tells you to buy or sell, and it can be wrong, so check the numbers.
High-signal only
Auto-computed retracement of the trailing 52w low-high leg. Recomputed on each refresh; not a curated level.
Auto-computed retracement of the trailing 52w low-high leg. Recomputed on each refresh; not a curated level.
Auto-computed retracement of the trailing 52w low-high leg. Recomputed on each refresh; not a curated level.